Vicarious Surgical Inc
vicarioussurgical.comVicarious Surgical Inc (NYSE: RBOT) is a pre-commercial surgical robotics company developing the Vicarious Surgical System, a robotic platform designed for minimally invasive abdominal procedures beginning with ventral hernia repair. The company has generated no product revenue as of the 10-K filed March 9, 2026, and remains in the development and regulatory clearance stage. The Vicarious Surgical System is designed with a smaller footprint than legacy robotic systems, intended to pass through standard hospital and operating room doorways and operate across multiple operating rooms without permanent room dedication. The company received FDA Breakthrough Device designation in November 2019 for an earlier device design, though subsequent design changes resulted in the current system no longer carrying that designation. Vicarious Surgical is headquartered in the United States and competes in the surgical robotics market against established robotic systems already in clinical use. Capital structure is equity-dependent, with the company relying on public markets to fund ongoing research, development, and pre-commercialization activities.
Products & Services
Vicarious Surgical System: a robotic surgical platform designed for minimally invasive procedures, initially targeting ventral hernia repair. The system is designed with a smaller footprint for mobility within medical facilities, intended to support use across multiple operating rooms. Maintenance and service support are intended to accompany system sales upon commercialization. As of the filing date, the system has not received FDA clearance or approval.
Revenue Model
No product revenue disclosed in the 10-K filed March 9, 2026. The company has not yet received FDA marketing authorization for the Vicarious Surgical System. Upon commercialization, the company has indicated intent to offer the system along with maintenance and service support at pricing positioned to be attractive relative to existing robotic systems, though no specific pricing model or revenue terms are disclosed.
Customers & Markets
Target customers are hospitals and ambulatory surgery centers (ASCs). The primary initial end market is ventral hernia repair procedures. Surgeon adoption and hospital utilization are identified as key demand drivers in the filing.
Geographic Exposure
United States primary regulatory focus, with the 10-K noting potential for clinical trial sites outside the United States, subject to FDA data acceptance conditions.
Financial Snapshot
Loading...
